You are here: Industry Insights > CAR-T

News List

bluebird bio Amends CAR-T Collaboration Agreement contractpharma
May 19, 2020
Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-U.S. territories.
Janssen's CAR-T shows 100% response rate in multiple myeloma pharmatimes
May 14, 2020
Janssen has unveiled updated results from a mid-stage trial of its CAR-T therapy JNJ-4528, showing high rates of response in patients with relapsed or refractory multiple myeloma.
Astellas, Adaptimmune to Co-Develop, Commercialize CAR-T and TCR T-Cell Therapies americanpharmaceuticalreview
January 19, 2020
Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting pharmaceutical-business-review
December 12, 2019
Novartis announced results from two analyses of real-world experience with Kymriah (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications.
Janssen Announces Initial Results for BCMA CAR-T Therapy JNJ-4528 americanpharmaceuticalreview
December 11, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced initial results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528) ...
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody En-CPhI.CN
December 10, 2019
CARsgen Therapeutics, a clinical-stage biopharmaceutical company committed to discovering and developing a combined platform of Chimeric Antigen Receptor T (CAR-T) cell therapies ...
Scottish Medicines Consortium approves Kymriah® CAR-T therapy europeanpharmaceuticalreview
September 12, 2019
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
Novartis’ CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market PharmaSources/Xiaoyaowan
August 27, 2019
Novartis develops the world’s first CAR T-cell therapy CTL019. And now the drug has been accepted by the CDE.
Medicare to Cover CAR-T Therapy for Leukemia, Lymphoma drugs
August 09, 2019
A breakthrough gene therapy will be covered for certain types of lymphoma and leukemia, Medicare says.
Servier Selects Yposkesi for CAR-T GMP-Mfg. contractpharma
June 10, 2019
Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T cell technology development.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page